<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.2d1 20170631//EN" "JATS-journalpublishing1.dtd">
      <Volume-Issue>Volume 14, Issue 04 , 2022 </Volume-Issue>
      <Season>October-December </Season>
      <ArticleTitle>Therapeutics perspectives of incredible probiotics</ArticleTitle>
      <Abstract>The health benefits provided by probiotics are a matter of exploration from last years. With the help of various mechanisms, a single probiotic can only be applicable for a certain clinical condition because a particular probiotic is effective against a specific disease. The information regarding the clinical data in various diseases is not sufficient. A literature search was performed by focusing on the mechanisms by which probiotics acting on various diseases, the safety of probiotics and clinical data which provide huge information regarding the efficacy and safety of probiotics. In case of skin problems such as skin aging and eczema, probiotics act by antioxidant and anti-inflammatory activity; in gastrointestinal tract (GIT) problem, probiotics act by balancing the GIT flora. Probiotics cause the mucosal immune system to secrete the protective immunoglobulin (Ig) in inflammatory bowel disease. It also treats urinary tract infection and vaginal infections by improving microbial growth. The clinical trial provides various evidence regarding the beneficial health effects of probiotics. This evidence confirms the use of probiotics in the prevention and treatment of medical conditions. Using probiotics as novel therapeutic strategies, it concluded that its contribution to treating different diseases is a safe and more efficient way.</Abstract>
      <Keywords>Antibiotic-associated diarrhea, Lactose metabolism, Probiotics, Ultraviolet protection, Urinary tract infection</Keywords>
        <Abstract>https://isfcppharmaspire.com/ubijournal-v1copy/journals/abstract.php?article_id=14355&amp;title=Therapeutics perspectives of incredible probiotics</Abstract>
        <References>1. Bhattacharya S. Probiotics and herbals as a boom in treatment of ulcerative colitis. Asian J Pharm 2020;14:301.&#13;
2. Singh A, Kaur K, Kaur V, Singh G, Mandal UK, Mishra N, et al. Importance of nanocarriers and probiotics in the treatment of ulcerative colitis. Int J Appl Pharm 2019;15:216-28.&#13;
3. Kechagia M, Basoulis D, Konstantopoulou S, Dimitriadi D, Gyftopoulou K, Skarmoutsou N, et al. Health benefits of probiotics: A review. ISRN Nutr 2013;2013:481651.&#13;
4. Shi LH, Balakrishnan K, Thiagarajah K, Ismail NI, Yin OS. Beneficial properties of probiotics. Trop Life Sci Res 2016;27:73.&#13;
5. Singh S, Kotla NG, Lal UR. Omnipresence of probiotics in diversified clinical practices. J Prob Health 2014;3:1-9.&#13;
6. Vouloumanou EK, Makris GC, Karageorgopoulos DE, Falagas ME. Probiotics for the prevention of respiratory tract infections: A systematic review. Int J Antimicrob&#13;
Agents 2009;34:10.e1-10.&#13;
7. Ganceviciene R, Liakou AI, Theodoridis A, Makrantonaki E, Zouboulis CC. Skin anti-aging strategies. Dermatoendocrinol 2012;4:308-19.&#13;
8. Zouboulis CC, Adjaye J, Akamatsu H, Moe-Behrens G, Niemann C. Human skin stem cells and the ageing process. Exp Gerontol 2008;43:986-97.&#13;
9. Satoh T, Murata M, Iwabuchi N, Odamaki T, Wakabayashi H, Yamauchi K, et al. Effect of Bifidobacterium breve B-3 on skin photoaging induced by chronic UV irradiation in mice. Benef Microbes 2015;6:497-504.&#13;
10. Panich U, Sittithumcharee G, Rathviboon N, Jirawatnotai S. Ultraviolet radiation-induced skin aging: The role of DNA damage and oxidative stress in epidermal stem cell damage mediated skin aging. Stem Cells Int 2016;2016:7370642.&#13;
11. Kim HM, Lee DE, Park SD, Kim YT, Kim YJ, Jeong JW, et al. Oral administration of Lactobacillus plantarum HY7714 protects hairless mouse against ultraviolet B-induced photoaging. J Microbiol Biotechnol 2014;24:1583-91.&#13;
12. Lee DE, Huh CS, Ra J, Choi ID, Jeong JW, Kim SH, et al. Clinical evidence of effects of Lactobacillus plantarum HY7714 on skin aging: A randomized, double blind, placebo-controlled study. J Microbiol Biotechnol 2015;25:2160-8.&#13;
13. Bouilly-Gauthier D, Jeannes C, Maubert Y, Duteil L, Queille-Roussel C, Piccardi N, et al. Clinical evidence of benefits of a dietary supplement containing probiotic&#13;
and carotenoids on ultraviolet-induced skin damage. Br J Dermatol 2010;163:536-43.&#13;
14. Hill C, Guarner F, Reid G, Gibson GR, Merenstein DJ, Pot B, et al. Expert consensus document. The International Scientific Association for Probiotics and Prebiotics consensus statement on the scope and appropriate use of the term probiotic. Nat Rev Gastroenterol Hepatol 2014;11:506-14.&#13;
15. Silverberg JI, Hanifin J, Simpson EL. Climatic factors are associated with childhood eczema prevalence in the United States. J Invest Dermatol 2013;133:1752-9.&#13;
16. Torii S, Torii A, Itoh K, Urisu A, Terada A, Fujisawa T, et al. Effects of oral administration of Lactobacillus acidophilus L-92 on the symptoms and serum markers of atopic dermatitis in children. Int Arch Allergy Immunol 2011;154:236-45.&#13;
17. Sawada J, Morita H, Tanaka A, Salminen S, He F, Matsuda H. Ingestion of heat-treated Lactobacillus rhamnosus GG prevents development of atopic dermatitis in NC/Nga mice. Clin Exp Allergy 2007;37:296-303.&#13;
18. Inoue R, Nishio A, Fukushima Y, Ushida K. Oral treatment with probiotic Lactobacillus johnsonii NCC533 (La1) for a specific part of the weaning period prevents the development of atopic dermatitis induced after maturation in model mice, NC/Nga. Br J Dermatol&#13;
19. Caffarelli C, Cavagni G, Deriu FM, Zanotti P, Atherton DJ. Gastrointestinal symptoms in atopic eczema. Arch Dis Child 1998;78:230-4.&#13;
20. Rather IA, Bajpai VK, Kumar S, Lim J, Paek WK, Park YH. Probiotics and atopic dermatitis: An overview. Front Microbiol 2016;7:507.&#13;
21. Drago L, De Vecchi E, Toscano M, Vassena C, Altomare G, Pigatto P. Treatment of atopic dermatitis eczema with a high concentration of Lactobacillus salivarius LS01 associated with an innovative gelling complex: A pilot study on adults. J Clin Gastroenterol 2014;48 Suppl 1:S47-51.&#13;
22. Mattar R, de Campos Mazo DF, Carrilho FJ. Lactose intolerance: Diagnosis, genetic, and clinical factors. Clin Exp Gastroenterol 2012;5:113-21.&#13;
23. Oak SJ, Jha R. The effects of probiotics in lactose intolerance: A systematic review. Crit Rev Food Sci Nutr 2019;59:1675-83.&#13;
24. Dhama K, Latheef SK, Munjal AK, Khandia R,Samad HA, Iqbal HMN, et al. Probiotics in curing allergic and inflammatory conditions-research progress and futuristic vision. Recent Pat Inflamm Allergy Drug Discov 2017;10:105-18.&#13;
25. He T, Priebe MG, Zhong Y, Huang C, Harmsen HJ, Raangs GC, et al. Effects of yogurt and Bifidobacteria supplementation on the colonic microbiota in lactoseintolerant subjects. J Appl Microbiol 2008;104:595-604.&#13;
26. Pakdaman MN, Udani JK, Molina JP, Shahani M. The effects of the DDS-1 strain of Lactobacillus on symptomatic relief for lactose intolerance-a randomized, double-blind, placebo-controlled, crossover clinical trial. Nutr J 2015;15:56.&#13;
27. Ojetti V, Gigante G, Ainora ME, Gabrielli M, Migneco A, Gasbarrini G, et al. S1213 the effect of oral supplementation with Lactobacillus reuteri or tilactase in lactose-intolerant patients: A placebo controlled study. Gastroenterology 2009;136:A-214.&#13;
28. Hand;ouml;genauer C, Hammer HF, Krejs GJ, Reisinger EC. Mechanisms and management of antibiotic-associated diarrhea. Clin Infect Dis 1998;27:702-10.&#13;
29. Katz JA. Probiotics for the prevention of antibioticassociated diarrhea and Clostridium difficile diarrhea. J Clin Gastroenterol 2006;40:249-55.&#13;
30. Varughese CA, Vakil NH, Phillips KM. Antibioticassociated diarrhea: A refresher on causes and possibleprevention with probiotics-continuing education article. J Pharm Pract 2013;26:476-82.&#13;
31. Mantegazza C, Molinari P, D’Auria E, Sonnino M, Morelli L, Zuccotti GV. Probiotics and antibioticassociated diarrhea in children: A review and new evidence on Lactobacillus rhamnosus GG during and after antibiotic treatment. Pharmacol Res 2018;128:63-72.&#13;
32. Olek A, Woynarowski M, Ahrand;eacute;n IL, Kierku? J, Socha P, Larsson N, et al. Efficacy and safety of Lactobacillus plantarum DSM 9843 (LP299V) in the prevention of antibiotic-associated gastrointestinal symptoms in children-randomized, double-blind, placebo-controlled study. J Pediatr 2017;186:82-6.&#13;
33. Ko?odziej M, Szajewska H. Lactobacillus reuteri DSM 17938 in the prevention of antibiotic-associated diarrhoea in children: Protocol of a randomised controlled trial. BMJ Open 2017;7:e013928.&#13;
34. Ofosu A. Clostridium difficile infection: A review of current and emerging therapies. Ann Gastroenterol 2016;29:147-54.&#13;
35. Sun X, Savidge T, Feng H. The enterotoxicity ofClostridium difficile toxins. Toxins (Basel) 2010;2:1848-80.&#13;
36. Fordtran JS. Colitis due to Clostridium difficile toxins: Underdiagnosed, highly virulent, and nosocomial. Proc (Bayl Univ Med Cent) 2006;19:3-12.&#13;
37. McFarland LV. Evidence-based review of probiotics for antibiotic-associated diarrhea and Clostridium difficile infections. Anaerobe 2009;15:274-80.&#13;
38. Buts JP. Twenty-five years of research on Saccharomyces boulardii trophic effects: Updates and perspectives. Dig Dis Sci 2009;54:15-8.&#13;
39. Kekkonen RA, Sysi-Aho M, Seppanen-Laakso T, Julkunen I, Vapaatalo H, Oresic M, et al. Effect of probiotic Lactobacillus rhamnosus GG intervention on global serum lipidomic profiles in healthy adults. World J Gastroenterol 2008;14:3188-94.&#13;
40. Bruewer M, Luegering A, Kucharzik T, Parkos CA, Madara JL, Hopkins AM, et al. Proinflammatory cytokines disrupt epithelial barrier function by apoptosisindependent mechanisms. J Immunol 2003;171:6164-72.&#13;
41. McFarland LV, Surawicz CM, Greenberg RN, Fekety R, Elmer GW, Moyer KA, et al. A randomized placebo-controlled trial of Saccharomyces boulardii in combination with standard antibiotics for Clostridium difficile disease. JAMA 1994;271:1913-8.&#13;
42. Surawicz CM, McFarland LV, Greenberg RN, Rubin M, Fekety R, Mulligan ME, et al. The search for a better treatment for recurrent Clostridium difficile disease: Use of high-dose vancomycin combined with Saccharomyces boulardii. Clin Infect Dis 2000;31:1012-7.&#13;
43. Pochapin M. The effect of probiotics on Clostridium difficile diarrhea. Am J Gastroenterol 2000;95:S11-3.&#13;
44. Lawrence SJ, Korzenik JR, Mundy LM. Probiotics for recurrent Clostridium difficile disease. J Med Microbiol 2005;54:905-6.&#13;
45. Saha L. Irritable bowel syndrome: Pathogenesis, diagnosis, treatment, and evidence-based medicine. World J Gastroenterol 2014;20:6759-73.&#13;
46. Vahedi H, Ansari R, Mir-Nasseri M, Jafari E. Irritable bowel syndrome: A review article. Middle East J Dig Dis 2010;2:66-77.&#13;
47. Aragon G, Graham DB, Borum M, Doman DB. Probiotic therapy for irritable bowel syndrome. Gastroenterol Hepatol (N Y) 2010;6:39-44.&#13;
48. Hisamatsu T, Inoue N, Yajima T, Izumiya M, Ichikawa H, Hibi T. Psychological aspects of inflammatory bowel disease. J Gastroenterol 2007;42 Suppl 17:34-40.&#13;
49. O’Mahony L, McCarthy J, Kelly P, Hurley G, Luo F, Chen K, et al. Lactobacillus and Bifidobacterium in irritable bowel syndrome: Symptom responses and relationship to cytokine profiles. Gastroenterology 2005;128:541-51.&#13;
50. Guyonnet D, Chassany O, Ducrotte P, Picard C, Mouret M, Mercier CH, et al. Effect of a fermented milk containing Bifidobacterium animalis DN-173 010 on the health-related quality of life and symptoms in irritable bowel syndrome in adults in primary care: A multicentre, randomized, double-blind, controlled trial. Aliment&#13;
Pharmacol Ther 2007;26:475-86.&#13;
51. Niv E, Naftali T, Hallak R, Vaisman N. The efficacy of Lactobacillus reuteri ATCC 55730 in the treatment of patients with irritable bowel syndrome-a double blind, placebo-controlled, randomized study. Clin Nutr 2005;24:925-31.&#13;
52. Hosseini A, Nikfar S, Abdollahi M. Probiotics use to treat irritable bowel syndrome. Expert Opin Biol Ther 2012;12:1323-34.&#13;
53. Dai C, Zheng CQ, Jiang M, Ma XY, Jiang LJ. Probiotics and irritable bowel syndrome. World J Gastroenterol 2013;19:5973-80.&#13;
54. Roberts LM, McCahon D, Holder R, Wilson S, Hobbs FD. A randomised controlled trial of a probiotic ‘functional food’ in the management of irritable bowel syndrome. BMC Gastroenterol 2013;13:45.&#13;
55. Lyra A, Hilliland;auml; M, Huttunen T, Mand;auml;nnikkand;ouml; S, Taalikka M, Tenniland;auml; J, et al. Irritable bowel syndrome symptom severity improves equally with probiotic and placeboWorld J Gastroenterol 2016;22:10631-42.&#13;
56. Ba?tand;uuml;rk A, Artan R, Y?lmaz A. Efficacy of synbiotic, probiotic, and prebiotic treatments for irritable bowelsyndrome in children: A randomized controlled trial. Turk J Gastroenterol 2016;27:439-43.&#13;
57. Orenstein R, Wong ES. Urinary tract infections in adults. Am Fam Physician 1999;59:1225-34, 1237.&#13;
58. Laupland KB, Ross T, Pitout JD, Church DL, Gregson DB. Community-onset urinary tract infections: A populationbased assessment. Infection 2007;35:150-3.&#13;
59. Siliano PR, Rocha LA, Medina-Pestana JO, Heilberg IP. The role of host factors and bacterial virulence genes in the development of pyelonephritis caused by Escherichia coli in renal transplant recipients. Clin J Am Soc Nephrol 2010;5:1290-7.&#13;
60. Johnson JR, Kuskowski MA, O’bryan TT, Colodner R, Raz R. Virulence genotype and phylogenetic origin in relation to antibiotic resistance profile among Escherichia coli urine sample isolates from Israeli women with acute uncomplicated cystitis. Antimicrob Agents Chemother 2005;49:26-31.&#13;
61. Samie A, editor. Escherichia coli: Recent Advances on Physiology, Pathogenesis and Biotechnological Applications. BoD-Books on Demand. London: InTechOpen; 2017.&#13;
62. Salva S, Villena J, Herrera M, Alvarez S. Can immunobiotics beneficially modulate hemato-immune responses in immunocompromised hosts? In: Probiotics: Immunobiotics and Immunogenics. Boca Raton: CRC Press; 2013. p. 280.&#13;
63. Alves L, de Vries CG, David S, Weda M. Toepassing van antibiotica en alternatieven; Kansen en belemmeringen. 2019.&#13;
64. Lee BB, Toh SL, Ryan S, Simpson JM, Clezy K, Bossa L, et al. Probiotics [LGG-BB12 or RC14-GR1] versus placebo as prophylaxis for urinary tract infection in&#13;
persons with spinal cord injury [ProSCIUTTU]: A study protocol for a randomised controlled trial. BMC Urol 2016;16:18.&#13;
65. Schwenger EM, Tejani AM, Loewen PS. Probiotics for preventing urinary tract infections in adults and children. Cochrane Database Syst Rev 2015;2015:CD008772.&#13;
66. Silva de Ruiz C, Land;oacute;pez de Bocanera ME, Nader de Macand;iacute;as ME, Pesce de Ruiz Holgado AA. Effect of Lactobacilli and antibiotics on E. coli urinary infections in mice. Biol Pharm Bull 1996;19:88-93.&#13;
67. Uehara S, Monden K, Nomoto K, Seno Y, Kariyama R, Kumon H. A pilot study evaluating the safety and effectiveness of Lactobacillus vaginal suppositories in patients with recurrent urinary tract infection. Int J Antimicrob Agents 2006;28 Suppl 1:S30-4.&#13;
68. Czaja CA, Stapleton AE, Yarova-Yarovaya Y, Stamm WE. Phase I trial of a Lactobacillus crispatus vaginal suppository for prevention of recurrent urinary tract infection in women. Infect Dis Obstet Gynecol 2007;2007:35387.&#13;
69. Nicolle LE. Uncomplicated urinary tract infection in adults including uncomplicated pyelonephritis. Urol Cli North Am 2008;35:1-12, v.&#13;
70. Mulu W, Yimer M, Zenebe Y, Abera B. Common causes of vaginal infections and antibiotic susceptibility of aerobic bacterial isolates in women of reproductive age attending at Felegehiwot Referral Hospital, Ethiopia: A cross sectional study. BMC Womens Health 2015;15:42.&#13;
71. Haltas H, Bayrak R, Yenidunya S. To determine of the prevalence of bacterial vaginosis, Candida sp, mixed infections (Bacterial Vaginosis + Candida sp), Trichomonas Vaginalis, Actinomyces sp in Turkish women from Ankara, Turkey. Ginekol Pol 2012;83:744-8.&#13;
72. Amsel R, Totten PA, Spiegel CA, Chen KC, Eschenbach D, Holmes KK. Nonspecific vaginitis. Diagnostic criteria and microbial and epidemiologic associations. Am J Med&#13;
73. Dover SE, Aroutcheva AA, Faro S, Chikindas ML. Natural antimicrobials and their role in vaginal health: A short review. Int J Probiotics Prebiotics 2008;3:219-30.&#13;
74. Valore EV, Park CH, Igreti SL, Ganz T. Antimicrobial components of vaginal fluid. Am J Obstet Gynecol 2002;187:561-8.&#13;
75. Juand;aacute;rez Tomand;aacute;s MS, Ocaand;ntilde;a VS, Wiese B, Nader-Macand;iacute;as ME. Growth and lactic acid production by vaginalLactobacillus acidophilus CRL 1259, and inhibition of uropathogenic Escherichia coli. J Med Microbiol 2003;52:1117-24.&#13;
76. Boskey ER, Cone RA, Whaley KJ, Moench TR. Origins of vaginal acidity: High D/L lactate ratio is consistent with bacteria being the primary source. Hum Reprod 2001;16:1809-13.&#13;
77. Cribby S, Taylor M, Reid G. Vaginal microbiota and the use of probiotics. Interdiscip Perspect Infect Dis 2008;2008:256490.&#13;
78. Chan RC, Bruce AW, Reid G. Adherence of cervical, vaginal and distal urethral normal microbial flora to human uroepithelial cells and the inhibition of adherence of Gram-negative uropathogens by competitive exclusion.&#13;
J Urol 1984;131:596-601.&#13;
79. Raz R, Colodner R, Rohana Y, Battino S, Rottensterich E, Wasser I, et al. Effectiveness of estriol-containing vaginal pessaries and nitrofurantoin macrocrystal therapy in the prevention of recurrent urinary tract infection in postmenopausal women. Clin Infect Dis 2003;36:1362-8.&#13;
80. Vicariotto F, Mogna L, Del Piano M. Effectiveness of the two microorganisms Lactobacillus fermentum LF15 and Lactobacillus plantarum LP01, formulated in slow release vaginal tablets, in women affected by bacterial vaginosis: A pilot study. J Clin Gastroenterol 2014;48 Suppl 1:S106-12.&#13;
81. Rand;oslash; ADB, Simpson MR, Rand;oslash; TB, Storrand;oslash; O, Johnsen R, Videm V, et al. Reduced Th22 cell proportion and prevention of atopic dermatitis in infants following maternal probiotic supplementation. Clin Exp Allergy 2017;47:1014-21.&#13;
82. Wang IJ, Wang JY. Children with atopic dermatitis show clinical improvement after Lactobacillus exposure. Clin Exp Allergy 2015;45:779-87.&#13;
83. Chatterjee S, Kar P, Das T, Ray S, Gangulyt S, Rajendiran C, et al. Randomised placebo-controlled double blind multicentric trial on efficacy and safety of Lactobacillus acidophilus LA-5 and Bifidobacterium BB-12 for prevention of antibiotic-associated diarrhoea. J Assoc Physicians India 2013;61:708-12.&#13;
84. Cimperman L, Bayless G, Best K, Diligente A, Mordarski B, Oster M, et al. A randomized, double-blind, placebo-controlled pilot study of Lactobacillus reuteri ATCC 55730 for the prevention of antibiotic-associated diarrhea in hospitalized adults. J Clin Gastroenterol 2011;45:785-9.&#13;
85. Nobutani K, Sawada D, Fujiwara S, Kuwano Y, Nishida K, Nakayama J, et al. The effects of administration of the Lactobacillus gasseri strain CP 2305 on quality of life,&#13;
clinical symptoms and changes in gene expression in patients with irritable bowel syndrome. J Appl Microbiol 2017;122:212-24.&#13;
86. Ho M, Chang YY, Chang WC, Lin HC, Wang MH, Lin WC, et al. Oral Lactobacillus rhamnosus GR-1 and Lactobacillus reuteri RC-14 to reduce Group B Streptococcus colonization in pregnant women:&#13;
A randomized controlled trial. Taiwan J Obstet Gynecol&#13;